SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

Clinical and Experimental Metastasis

Volumn 20, Issue 8, 2003, Pages 757-766

  Murray, Lesley J ^a,c   Abrams, Tinya J ^a   Long, Kelly R ^b   Ngai, Theresa J ^a   Olson, Lisa M ^b   Hong, Weiru ^a   Keast, Paul K ^a   Brassard, Jacqueline A ^b   O'Farrell, Anne Marie ^a   Cherrington, Julie M ^a   Pryer, Nancy K ^a  

^a SUGEN INC   (United States)

^b Pharmacia Research   (United States)

^c NONE   (United States)

Author keywords

435 HAL Luc; Bioluminescence imaging; Breast cancer; CSF 1R; Metastasis; Osteoclast

Indexed keywords

COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDINOLINE; SUNITINIB;

ANIMAL CELL; ARTICLE; BIOLUMINESCENCE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; EVALUATION; EXPERIMENTAL MODEL; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN PHOSPHORYLATION; STATISTICAL SIGNIFICANCE; TUMOR MODEL;

EID: 9144274970     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CLIN.0000006873.65590.68     Document Type: Article

References (38)

1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61-6.
2. Perez EA. Current management of metastatic breast cancer. Semin Oncol 1999; 26: (4 Suppl 12): 1-10.
3. Clohisy DR, Perkins SL, Ramnaraine ML. Review of cellular mechanisms of tumor osteolysis. Clin Orthop 2000; 373: 104-14.
4. Kodama H, Yamasaki A, Nose M et al. Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. J Exp Med 1991; 173: 269-72.
5. Feng X, Takeshita S, Namba N et al. Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function. Endocrinology 2002; 143: 4868-74.
6. Insogna KL, Sahni M, Grey AB et al. Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts. J Clin Invest 1997; 100: 2476-85.
7. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37.
8. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-605.
9. Abrams T, Lee LB, Murray LJ et al. SU11248 inhibits kit and PDGFR beta in preclinical models of human small cell lung cancer. Mol Therapeutics 2003; 2: 471-8.
10. Laird AD, Cherrington JM. Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Expert Opin Invest Drugs 2003; 12: 51-64.
11. Schmidt CM, Settle SL, Keene JL et al. Characterization of spontaneous metastasis in an aggressive breast carcinoma model using flow cytometry. Clin Exp Metastasis 1999; 17: 537-44.
12. Harms JF, Welch DR. MDA-MB-435 human breast carcinoma metastasis to bone. Clin Exp Metastasis 2003; 20: 327-34.
13. Contag CH, Jenkins D and Contag PR et al. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2000; 2: 41-52.
14. Wetterwald A, van der Pluijm G, Que et al. Optical imaging of Cancer Metastasis to Bone Marrow: A mouse model of minimal residual disease. Am J Pathol 2002; 160: 1143-53.
15. Armstrong SA, Kung AL, Mabon ME et al. Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3: 173-83.
16. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48: 6876-81.
17. Robins SP, Duncan A, Wilson N et al. Standardization of pyridinium crosslinks, pyridinoline and deoxypyridinoline, for use as biochemical markers of collagen degradation. Clin Chem 1996; 42: 1621-6.
18. Buckley KA, Fraser WD. Receptor activator for nuclear factor kappaB ligand and osteoprotegerin:regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. Ann Clin Biochem 2002; 39: 551-6.
19. Zaidi M, Datta HK, Moonga BS et al. Evidence that the action of calcitonin on rat osteoclasts is mediated by two G proteins acting via separate post-receptor pathways. J Endocrinol 1990; 126: 473-81.
20. Hunt NC, Fujikawa Y, Sabokbar A et al. Cellular mechanisms of bone resorption in breast carcinoma. Br J Cancer 2001; 85: 78-84
21. Tamura H, Ishii S, Ikeda T et al. The relationship between urinary pyridinoline, deoxypyridinoline and bone metastasis in a rat breast cancer model. Breast Cancer 1999; 6: 23-8.
22. Smith IE. New drugs for breast cancer. Lancet 2002; 360: 790-2.
23. Mancino AT, Klimberg VS, Yamamoto M et al. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 2001; 100: 18-24.
24. Flick MM, Sapi E, Kacinski BM, Hormonal regulation of the c-fms proto-oncogene in breast cancer cells is mediated by a composite glucocorticoid response element. J Cell Biochem 2002; 85: 10-23.
25. Coussens LM, Werb Z. Inflammatory Cells and cancer: think different! J Exp Med 2001; 193: 23F.
26. Valkovic T, Dobrila F, Melato M et al. Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch 2002; 440: 583-8.
27. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002; 7: 177-89.
28. Lin EY, Nguyen AV, Russell RG et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193: F23-6.
29. Kacinski BM, Scata KA, Carter D et al. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 1991; 6: 941-52.
30. Flick MB, Sapi E, Perrotta PL et al. Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody. Oncogene 1997; 14: 2553-61.
31. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 1995; 27: 79-85.
32. Toy EP, Chambers JT, Kacinski BM et al. The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001; 80: 194-200.
33. Maher MG, Sapi E, Turner B et al. Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clin Cancer Res 1998; 4: 1851-6.
34. Tang R, Beuvon F, Ojeda M et al. M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes? J Cell Biochem 1992; 50: 350-6.
35. Kacinski BM. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol Reprod Dev 1997; 46: 71-4.
36. Yee LD, Liu L. The constitutive production of colony stimulating factor 1 by invasive human breast cancer cells. Anticancer Res 2000; 20: 4379-83.
37. McDermott RS, Deneux L, Mosseri V et al. Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur Cytokine Netw 2002; 13: 121-27.
38. Pickering LM, Mansi JL. The role of bisphosphonates in breast cancer management: review article. Curr Med Res Opin 2002; 18: 284-95.